___________________________

1  Non-GAAP net loss is calculated as GAAP net loss less the expense (or plus the income) associated with the change in fair value of the liability-classified warrants. Non-GAAP net loss per share is calculated by dividing the Non-GAAP net loss by the weighted average common shares outstanding.
ZIOPHARM Oncology, Inc.
Condensed Statements of Operations
(in thousands except share and per share data)
(unaudited)
         
  Three Months Ended December 31, Twelve Months Ended December 31,
  2012 2011 2012 2011
         
Revenue  $ 200  $ 200  $ 800  $ 667
         
Operating expenses:        
Research and development  34,982  12,650  83,446  57,083
General and administrative  4,061  3,967  19,523  14,984
Total operating expenses  39,043  16,617  102,969  72,067
         
Loss from operations  (38,843)  (16,417)  (102,169)  (71,400)
         
Other income (expense), net  52  13  (13)  39
Change in fair value of warrants  8,566  3,160  6,050  7,583
Net loss  $ (30,225)  $ (13,244)  $ (96,132)  $ (63,778)
         
         
Basic and diluted net loss per share  $ (0.37)  $ (0.19)  $ (1.22)  $ (0.97)
         
Weighted average common shares outstanding used to compute basic and diluted net loss per share  81,347,231  68,160,207  78,546,112  66,003,789
 
 
ZIOPHARM Oncology, Inc.
Balance Sheet Data
(in thousands)
(unaudited)
     
  December 31, 2012 December 31, 2011
     
Cash and cash equivalents  73,306  104,713
Working capital  61,412  92,742
Total assets  83,404  108,108
Total stockholders' equity   48,445  71,607
CONTACT: For ZIOPHARM         Nicole Jones         ZIOPHARM Oncology, Inc.         617-778-2266         njones@ziopharm.com                  Media Contacts:         David Schull or Lena Evans         Russo Partners, LLC         858-717-2310         212-845-4262         david.schull@russopartnersllc.com         lena.evans@russopartnersllc.com

ZIOPHARM Oncology, Inc. Logo

If you liked this article you might like

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Judgment Day; The Good, the Bad and the Ugly: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Don't Overlook Ziopharm Oncology